Exicure, Inc. (XCUR)

Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplant Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplant

REDWOOD CITY, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that it will present a poster at the upcoming 2026 Tandem Meetings | Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR), taking place February 4-7, 2026, in Salt Lake City, UT.

Exicure, Inc. (NASDAQ: XCUR - Get Free Report) was the recipient of a significant decline in short interest in the month of December. As of December 31st, there was short interest totaling 139,368 shares, a decline of 42.7% from the December 15th total of 243,112 shares. Currently, 4.6% of the shares of the stock are sold

Exicure, Inc. (NASDAQ: XCUR) stock is trading higher on Tuesday. Its session volume was 13.62 million, compared with the average volume of 151.41 thousand, according to data from Benzinga Pro.

Exicure (NASDAQ: XCUR), a clinical-stage biotechnology company specializing in next-generation stem-cell mobilization therapies, has staged a massive rally as investors reacted to the company's new breakthrough products.

REDWOOD CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced positive results from its completed Phase 2 trial evaluating burixafor (GPC-100) in combination with propranolol and granulocyte colony-stimulating factor (G-CSF) for the mobilization of hematopoietic progenitor cells (HPCs) in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation (AHCT). The data, which showed that approximately 90% of study participants achieved the primary endpoint, were presented today in an oral session at the 67th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.

REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the fiscal quarter ended September 30, 2025.

REDWOOD CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that results from its completed Phase 2 study evaluating burixafor, a small molecule CXCR4 antagonist, will be featured in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6-9, 2025, in Orlando, Florida.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Exicure, Inc. (NASDAQ: XCUR) breached their fiduciary duties to shareholders. If you currently own Exicure stock and acquired shares on or before January 7, 2021, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more ab.

Burixafor (GPC-100) Phase 2 Trial in Multiple Myeloma Nears Key Readout Preparing for Expansion into Sickle Cell Disease and Acute Myeloid Leukemia New Leadership Appointments Bring Deep Drug Development Expertise REDWOOD CITY, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today shared recent progress for its lead program, burixafor (GPC-100), outlined upcoming strategic priorities, and introduced new members of its leadership team who will help drive the company's next phase of growth.

Exicure Posts Wider Loss in Fiscal Q2

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Reports Second Quarter 2025 Financial Results.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Q1 2025 earnings release.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q.